Twice weekly treatment with recombinant IL-22 reduced serum FITC levels in Mtb-infected T2DM mice (185.31 ± 28.8 vs. 141.4 ± 34.8, p<0.05; S13A and S13B Fig). Here, IL22 is linked to type 2 diabetes mellitus.